USP2 and cancer: ML364 has been identified as a potential small molecule inhibitor of USP2 with an IC50 of 1.1 μM, which induces cellular cyclin D1 degradation leading to cell-cycle arrest in HCT116 cancer cell lines and also has a lower affinity to USP8 [209].